HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients

2014 ◽  
Vol 3 (6) ◽  
pp. 743
Author(s):  
R. Abolfazli ◽  
S. Samadzadeh ◽  
E. Tabibian ◽  
A. Shakoori ◽  
S.R. Dehgolan
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients

scholarly journals Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort

2012 ◽  
Vol 70 (10) ◽  
pp. 774-779 ◽  
Author(s):  
Valéria Coelho Santa Rita Pereira ◽  
Fabíola Rachid Malfetano ◽  
Isabella D'Andrea Meira ◽  
Letícia Fêzer de Souza ◽  
Assuncion Martinez Liem ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Treatment Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Response To Treatment ◽  
Clinical Criteria ◽  
Significant Difference ◽  
One Year ◽  
Multiple Sclerosis Patients

INTRODUCTION: Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE: It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among relapsing-remitting multiple sclerosis (RRMS) patients. METHODS: We analyzed treatment response to IFNb and GA in ninety-one RRMS patients followed for at least one year. Clinical response was established by clinical criteria based on relapses, disability progression or both. RESULTS: We observed a proportion of nonresponders, ranging from 3.3 to 42.9%, depending on the stringency of the criteria used. CONCLUSIONS: Our sample of Brazilian patients with MS has similarities when compared to other studies and there was no statistically significant difference regarding age, gender, ethnicity or disease duration between responders and nonresponders.

Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

2018 ◽  
Vol 39 (8) ◽  
pp. 1423-1430 ◽  
Author(s):  
Bonaventura Casanova ◽  
Laura Lacruz ◽  
María Luisa Villar ◽  
José Andrés Domínguez ◽  
María Carcelén Gadea ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients

Relationship between HLA-DRB1 genotype and clinical response to interferon-beta among Iranian multiple sclerosis patients

2015 ◽  
Vol 357 ◽  
pp. e295
Author(s):  
R. Abolfazli ◽  
S. Samadzadeh ◽  
E. Tabibian ◽  
A. Shakoori ◽  
T. Sabokbar ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients

Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients

2016 ◽  
Vol 263 (4) ◽  
pp. 722-729 ◽  
Author(s):  
Elisabet Matas ◽  
Laura Bau ◽  
María Martínez-Iniesta ◽  
Lucía Romero-Pinel ◽  
Maria Alba Mañé-Martínez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients

Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?

2000 ◽  
Vol 178 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Luca Durelli ◽  
Alessandra Oggero ◽  
Elisabetta Verdun ◽  
Gianluca Isoardo ◽  
Alessandra Ricci ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Interferon Beta ◽  
High Dose ◽  
Multiple Sclerosis Patients ◽  
High Dose Interferon

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients

2015 ◽  
Vol 352 (1-2) ◽  
pp. 37-40 ◽  
Author(s):  
Sara Samadzadeh ◽  
Elnaz Tabibian ◽  
Tayebeh Sabokbar ◽  
Abbas Shakoori ◽  
Shahram Rahimi Dehgolan ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients
Sign in / Sign up

Export Citation Format

Share Document